Other languages Laekna, Inc.

Equities

2105

KYG5340S1093

Delayed Hong Kong S.E. Other stock markets 08:48:59 04/06/2024 am IST			5-day change	1st Jan Change
6.86 ^HKD	+3.78%		-2.56%	-65.53%

30/05	Laekna Enlists First Patient for Phase 3 Trial for Breast Cancer Treatment in China; Shares Rise 4%	MT
30/05	Laekna, Inc. Announces First Patient Enrolled in Phase III Clinical Trial of LAE002 (AFURESERTIB) Plus Fulvestrant in Patients with HR+/HER2- Local Advanced or Metastatic Breast Cancer	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Laekna Enlists First Patient for Phase 3 Trial for Breast Cancer Treatment in China; Shares Rise 4%	30/05
Laekna, Inc. Announces First Patient Enrolled in Phase III Clinical Trial of LAE002 (AFURESERTIB) Plus Fulvestrant in Patients with HR+/HER2- Local Advanced or Metastatic Breast Cancer	30/05
Laekna Announces FDA Approval for the Phase III Clinical Trial Protocol of LAE002 (Afuresertib) PLUS LAE001 for the Treatment of Prostate Cancer	23/05
US FDA Gives Green Light to Laekna's Phase 3 Trial for Prostate Cancer Drug; Shares Rise 8%	23/05
Laekna, Inc. Announces Approval by the U.S. Food and Drug Administrationfor the Phase III Clinical Trial Protocol Of LAE002 (Afuresertib) Plus LAE001 for the Treatment Ofprostate Cancer	23/05
Laekna Gets Investigational New Drug Approval from Chinese Regulator for Obesity Drug	10/05
Lekna, Inc. Obtains IND Approval from the CDE for LAE102	10/05
Laekna Releases 2023 ESG Report	29/04
Laekna Scores FDA Nod for Obesity Drug LAE102	15/04
Lekna, Inc. Obtains Investigational New Drug Approval from the U.S. Food and Drug Administration for LAE102	15/04
Laekna Shrinks Loss in Fiscal 2023	27/03
Laekna, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
Laekna Submits New Drug Application to US FDA for Anti-Obesity Drug	11/03
Lekna, Inc. Submits Investigational New Drug Application for LAE102 for the Treatment of Obtains Treatment of Obtains Treatment to the U.S. Food and Drug Administration	11/03
Laekna's LAE102 IND Application Accepted by Chinese Drug Authorities	01/03
Laekna, Inc. Announces the Centre for Drug Evaluation of the National Medical Products Administration of China Accepts the Investigational New Drug Application for Lae102	29/02
Laekna, Inc. Announces Management Changes	02/02
Laekna's Phase 2 Trial for Ovarian Cancer Treatment Shows Reduced Risk of Disease Progression; Shares Plunge 34%	29/01
Laekna, Inc. Announces Top-Line Data of the Global MRCT Phase II Registrational Trial (PROFECTA-II) in Both the U.S. and China	28/01
Laekna, Inc. Announces Appointment of Chau Kwok Keung as Chief Financial Officer	15/01

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Laekna, Inc.

Equities

2105

KYG5340S1093

Other languages

Filters